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Treatment outcomes of drug-resistant
tuberculosis in the Netherlands, 2005–2015
Ivan S. Pradipta1,2,3* , Natasha van’t Boveneind-Vrubleuskaya4,5, Onno W. Akkerman6,7,
Jan-Willem C. Alffenaar4,8,9 and Eelko Hak1
Abstract
Background: Since in low incidence TB countries population migration and complex treatment of drug-resistant
tuberculosis (DR-TB) patients are major issues, we aimed to analyse patient risk factors associated with the incidence of
poor outcome of TB treatment among DR-TB patients in the Netherlands.
Methods: This retrospective cohort study included adult patients with confirmed DR-TB treated from 2005
to 2015. We obtained data from a nationwide exhaustive registry of tuberculosis patients in the Netherlands. Predictors
for unsuccessful TB treatment (defaulted and failed treatment) and TB-associated mortality were analysed using
multivariate logistic regression.
Results: Among 10,303 registered TB patients, 545 patients with DR-TB were analysed. Six types of DR-TB were identified
from the included patients, i.e. isoniazid mono- or poly-resistance (68%); rifampicin mono- or poly-resistance (3.1%);
pyrazinamide mono-resistance (8.3%); ethambutol mono-resistance (0.1%); multidrug-resistance (18.9%); and extensively
drug-resistance (0.7%). The majority of patients were foreign-born (86%) and newly diagnosed TB (89%) patients. The
cumulative incidence of unsuccessful treatment and mortality were 5 and 1%, respectively. Among all DR-TB cases,
patients with Multi Drug-Resistant Tuberculosis (MDR-TB) (OR 4.43; 95%CI 1.70–11.60) were more likely to have
unsuccessful treatment, while miliary and central nervous system TB (OR 15.60; 95%CI 2.18–111.52) may also be predictors
for TB mortality. Additionally, patients with substance abuse and homelessness tend to have unsuccessful treatment.
Conclusions: In recent years, we identified a low incidence of DR-TB as well as the poor outcome of DR-TB treatment.
The majority of cases were primary drug-resistant and foreign-born. To further improve treatment outcome, special
attention should be given to the high-risk DR-TB patients.
Keywords: Tuberculosis, Risk factors, Predictors, Unsuccessful treatment, Mortality, Epidemiology
Background
Drug-resistant tuberculosis (DR-TB), infection with a
strain of M. tuberculosis (M. tb) that is resistant to one or
more of the first-line anti-tuberculosis drug, is an ongoing
global threat. DR-TB can be classified into mono-, rifam-
picin-, poly-, multidrug- and extensive drug- resistance.
The World Health Organization (WHO) globally recorded
160,684 cases of multidrug-resistant/ rifampicin-resistant
tuberculosis (MDR/RR-TB) in 2017 [1]. However,
treatment success remains low at 55% globally [1] and the
cost of treating Multi- or Extensively Drug-resistant Tu-
berculosis (M/XDR-TB) is up to 25 times higher than the
cost of drug-susceptible tuberculosis [2].
Although in the WHO European region the fastest
decline in incidence and mortality rate of TB has been
reported since 2010 [3], DR-TB remains out of control.
One-third of notified MDR-TB cases identified globally
are people who live in the WHO European Region, and
additional resistance commonly exists with MDR-TB in
this region [4]. Furthermore, XDR-TB shows an increas-
ing trend. Among 91.3% second-line Drug Susceptibility
Test (DST), 18.6% of pulmonary MDR-TB cases had
XDR-TB in 2017 [5]. A recent study showed different
rates of treatment success, treatment failure and death
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: ivanpradipta@unpad.ac.id; i.s.pradipta@rug.nl
1Groningen Research Institute of Pharmacy, Unit of Pharmaco-Therapy, -
Epidemiology & - Economics (PTE2), University of Groningen, Antonius
Deusinglaan 1, 9713, AV, Groningen, the Netherlands
2Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy,
Universitas Padjadjaran, Jawa Barat, Indonesia
Full list of author information is available at the end of the article
Pradipta et al. Antimicrobial Resistance and Infection Control           (2019) 8:115 
https://doi.org/10.1186/s13756-019-0561-z
of MDR-TB patients in 16 European countries [6]. The
problem is more complex as travel and migration of
people have been identified as a risk factor of TB burden
in the European countries [7, 8]. This can lead to the
transmission of DR-TB from high to low incidence TB
countries which in increasingly being reported from
some European countries [9, 10].
The Netherlands is one of the low incidence TB coun-
tries [8]. The government has formulated a national tuber-
culosis control plan that set 1 case/100.000 people as a
target for TB elimination by 2035 [11]. Previously
published studies reported highly successful treatment of
MDR-TB in the Netherlands from 1985 to 2009 [12, 13].
However, these studies neither analysed all types of drug-
resistant TB nor identified predictors for poor outcome of
TB treatment. Hence, updated data are required to de-
scribe the current situation, evaluate current programmes
and identify potential interventions to improve treatment
outcomes of the overall DR-TB types in the Netherlands
as well as to achieve the national target. Since mono- or
poly-resistant TB can potentially develop into the poor
outcome of TB treatment and a further level of resistance,
we therefore aimed to determine the prevalence of differ-
ent types of DR-TB cases and its characteristics of the not-
evaluated patient for the treatment outcome over the re-
cent years from 2005 to 2015 in the Netherlands. Add-
itionally, we also examined the incidence and predictors
for poor outcome of TB treatment among all DR-TB pa-
tients and the subgroup of MDR-TB patients.
Methods
Study design and setting
We conducted a retrospective cohort study using a data-
base from the Netherlands Tuberculosis Registry (NTR)
covering the period from January 1, 2005 to December 31,
2015. De-identified data were obtained from the NTR on
January 23, 2018. The NTR is an exhaustive nationwide
database for tuberculosis disease in the Netherlands man-
aged by the Dutch National Institute for Public Health
and the Environment (RIVM). Real-time surveillance data
are routinely collected by RIVM in close collaboration
with the TB control department of the Municipal Public
Health Services (MPHS) and the Royal Netherlands
Tuberculosis Association (KNCV). NTR data collection
occurs throughout the TB diagnostic and treatment
period, and the information is entered by the physician or
nurse into an electronic report via the Online Registration
System for Infectious Diseases in the Infectious Diseases
Surveillance Information System (OSIRIS) after the
diagnosis is made. The data were validated by KNCV and
MPHS for the completeness and consistency through an
interactive process [14]. MPHS received reminders when
the data entered in OSIRIS were incomplete and online
system enables MPHS to correct and add the information.
Study patients
In the present study, adult DR-TB patients in the
Netherlands were our population of interest. We included
adult patients 18 years and older who were diagnosed with
tuberculosis disease during the period 2005–2015, caused
by M. tb pathogen proven to be resistant to at least one of
the first-line antituberculosis drugs. A phenotypical con-
firmation test has been used as a standard test in the
Netherlands between 2005 and 2007. However, a combin-
ation test, i.e., phenotypic test (Bactec MGIT 960 system)
and genotypic test (Genotype MTBDR plus assay or Line
Probe Assay (LPA)), have been applied since 2007. Drug
susceptibility testing (DST) was conducted to determine
resistance to first-line anti-tuberculosis drugs. If the resist-
ance had been confirmed, the DST was extended to the
second-line drugs, except for isoniazid, pyrazinamide
and ethambutol mono-resistance. We retrospectively
followed-up up to 24 months for patients identified as
DR-TB. The observation was started from the time the
diagnosis of DR-TB was made to the outcome of TB
treatment was reported. Patients who had not started
treatment and had an unknown treatment outcome
were excluded from the analysis for the incidence and
patient risk factors for poor outcome of TB treatment.
Moreover, patients who had an unknown treatment
outcome were included for further analysis of a not-
evaluated patient outcome.
Potential predictors and definitions
Potential predictors were identified at baseline of TB
diagnosis, and were selected from a previous meta-
analytical study [15], input from TB practitioners and
information from the NTR database. Five categories of po-
tential predictors were analysed in this study, including
socio-demographic information (age, gender, country of
birth, and domicile area), current TB diagnosis (type of
pulmonary TB diagnosis, initial TB location, country of
the TB diagnosis, and type of drug resistance), history of
TB disease and treatment (BCG vaccination, previously
diagnosed TB and treated latent TB infection / LTBI), risk
groups (TB contacts, immigrants, asylum seekers, home-
less individuals, health care workers, travellers from high
endemic area, prisoners, alcohol dependence, and drugs
dependence), and comorbidities (diabetes, malignancies,
HIV, renal insufficiency/on dialysis, and organ transplant-
ation). Operational definitions of the variables and termin-
ology followed the definitions stated in the OSIRIS and
WHO guideline [14, 16] (See Additional file 1: Table S1).
Study outcomes
We defined unsuccessful TB treatment and TB associated
mortality as the primary outcome for the predictors of
poor outcome treatment. Unsuccessful treatment was a
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combination of defaulted and failed treatments, while TB
associated mortality was mortality due to tuberculosis
disease that was defined by a doctor who treated the
patient. Defaulted treatment was defined as such if one of
the following four conditions was met: 1) an interruption
of TB treatment, that was not decided by the clinician, for
two or more consecutive months, 2) an uncompleted 6-
month treatment in a 9-month period, 3) an uncompleted
9-month treatment in a 12-month period, and 4) treat-
ments where patients took less than 80% of their medica-
tion [14, 16]. Failed treatments were defined as having a
TB-positive sputum smear or culture on the fifth month
or later after treatment initiation [14, 16]. In case of RR/
M/XDR-TB, treatment failure was defined if one of the
following five conditions was met: 1) lack of conversion by
the end of the intensive phase, 2) bacteriological reversion
in the continuation phase after conversion to negative, 3)
evidence of additional acquired resistance to fluoroquino-
lone or second-line injectable drugs 4) adverse drug reac-
tions, or 5) a TB-positive sputum smear or culture were
defined after 12month or later from the initial TB treat-
ment [14, 16]. As a secondary outcome, we studied the
characteristic of patients who were not evaluated for
the treatment outcome. The patient who started the
treatment but were unknown for the treatment out-
come, e.g., in transferred out cases, were defined as
not-evaluated patients.
Data analysis
We used descriptive analysis to describe characteristics
of the study patients, trends of DR-TB cases and inci-
dence of poor treatment outcomes during the study
period. The cumulative incidence was used to express
incidence for the poor outcome by dividing the number
of cases of poor outcomes of TB treatment (unsuccessful
treatment or TB-associated mortality) by the number of
patients diagnosed with DR-TB. A univariate analysis
was conducted for each of the potential predictors and
outcomes. We used the chi-square test or the Fisher’s
exact test (when expected cell size was < 5) for the
categorical data in the univariate analysis. Potential
predictors that had a p-value ≤0.15 were included in the
multivariate analysis. The logistic regression analysis
with a backward step elimination based on a p-value >
0.05 and entry method were used for the multivariate
analysis. We used a complete case analysis in the multi-
variate analysis considering the low percentage of the
missing data from the variables analysed. We identified
1 (0.2%) missing values for gender, 2 (0.4%) missing
values for country of birth, 53 (9.7%) missing values for
newly diagnosed TB, and 58 (10.6%) missing values for
previous LTBI treatment. Furthermore, some potential
predictors were not included in the analysis due to a
high level of missing values, i.e. presence of HIV (51%)
and BCG vaccination (51%). To quantify the level of the
association between predictors and the outcome, an
odds ratio (OR) with 95% confidence interval (95%CI)
was calculated. Calibration values of the final model
were assessed by the Hosmer-Lemeshow test. Statistical
Package for the Social Science version 23 was used for
the statistical analysis in this study, and we followed the
STROBE statement for reporting the study results [17].
Results
Out of 10,303 adult TB cases identified during the
study period, we included 545 (5.3%) DR-TB cases that
fulfilled criteria of the study (See flowchart in Fig. 1).
During the same period, the prevalence of MDR-TB
was 1% (n/N = 103/10,303).
We identified that the highest proportion of DR-TB
during the study period existed of isoniazid mono- or
poly-resistant TB cases (375 cases), while the highest
number of patients diagnosed with all type of DR-TB was
in 2010 (68 cases). As the second highest proportion of
DR-TBs, MDR-TB was identified in each of the years, with
103 diagnosed cases during the study period. However,
some types of DR-TB, such as rifampicin mono- or poly-
resistant strains, ethambutol mono-resistant and XDR-TB,
were not consistently found every year during the study
period. Overall, there was a declining trend of DR-TB
cases during the study period, from 54 cases (2005) to 33
cases (2015) (Fig. 2).
With regard to the patient risk factors, DR-TB pa-
tients were slightly more often in the male (54%), rural
domicile (66%), and pulmonary TB diagnosis (52%)
group, while most cases were newly diagnosed with
TB (88%), foreign-born (86%), isoniazid or rifampicin
mono−/poly-resistant TB (72%), with TB diagnosis in
the Netherlands (98%) and aged between 25 and 64
years old (74%) (Table 1).
As described in Fig. 1, we identified 28 patients with
unknown treatment outcome. We observed that previ-
ously diagnosed TB patients, illegal immigrants, travelers
from/in endemic areas and prisoners were more likely to
be not evaluated for their treatment outcome (p < 0.05)
(Additional file 1: Table S2).
Treatment outcomes and its predictors among the overall
drug-resistant tuberculosis patients
We observed that there was no failed treatment outcome
in DR-TB patients. The treatment outcomes among the
overall DR-TB patients (N = 545) were cured treatment
(n = 44), completed treatment (n = 463), defaulted
treatment (n = 25), TB-associated mortality (n = 6), and
non-TB-associated mortality (n = 7). Therefore, the
cumulative incidence of unsuccessful treatment and
death were 5 and 1%, respectively. In the univariate
analysis, several variables such as being male, having
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Fig. 1 Flow diagram of the included patients. *The proportion of drug-resistant M. tb complex was 8.2% (49/582); The proportion of
M. tb complex with the known type of strain was 1.2% (7/582)
Fig. 2 The number of drug-resistant cases in the Netherlands from 2005-2015. Notes: H, isoniazid; R, rifampicin; E, ethambutol; Z, pyrazinamide;
MDR, multidrug-resistant; XDR, extensively drug-resistant
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MDR-TB, homelessness, alcohol dependence, and sub-
stance abuse were significantly associated with unsuc-
cessful treatment (p < 0.05). Furthermore, we included
those predictors together with potential predictors that
have a p ≤ 0.15 in the multivariate analysis. Finally, we
identified three significant predictors (p < 0.05) for the
unsuccessful treatment of TB in the multivariate
analysis, i.e., having MDR-TB (OR 4.43; 95% CI 1.70–
11.60), homelessness (OR 9.10; 95% CI 2.32–35.74),
and substance abuse (OR 6.66; 95% CI 1.72–25.82).
Performance of the final model was acceptable, with a
Hosmer-Lemeshow test p-value of 0.88 (Table 2).
In a univariate analysis, we found miliary and central
nervous system (CNS) TB (OR 14.96; 95% CI 2.47–90.52)
as a potential predictor for the mortality outcome. Our
final model in the multivariate analysis showed that
miliary and CNS TB (OR 15.60; 95%CI 2.18–111.52) were
more prone to having death as an outcome than any other
TB site adjusted by variables of age and illegal immigrant.
Our final model demonstrated an acceptable calibration
with a Hosmer-Lemeshow test p-value of 0.85 (Table 3).
Treatment outcomes and its predictors among the
multidrug-resistant tuberculosis patients
Since MDR-TB was a risk factor for poor outcome treat-
ment among all DR-TB patients, we attempted to gain
more insight about the predictors of treatment outcome
in the subgroup of MDR-TB patients. We observed that
among the 103 MDR-TB cases, most cases were from the
group of foreign-born patients, followed by those living in
rural domiciles, having lung-TB, newly diagnosed with TB
without any previous TB treatment and identified as DR-
TB-positive in the Netherlands. Figure 2 reveals that there
has been a fluctuating trend in the number of MDR-TB
cases from 2005 to 2015. Treatment outcomes of the
MDR-TB patients (N = 103) were cured treatment
(n = 4), completed treatment (n = 85), defaulted treat-
ment (n = 11), TB associated mortality (n = 1), and
non-TB associated mortality (n = 2). Overall, the cu-
mulative poor TB treatment outcome incidence (a
combination of unsuccessful treatment and death due
to tuberculosis) was 12%. The significant differences
(p < 0.05) for the poor TB treatment outcome were
Table 1 Characteristics of patients (n = 545)













Rural domicileb 359 (65.9)




ETB + PTB 71 (13)
Type of TB location:
Lungs 333 (61.1)
Miliary and central nervous
system TB
13 (2.4)
Respiratory tract 38 (7)
Intestinal tract 15 (2.8)
Bone and joint 28 (5.1)
Urogenital tract 9 (1.7)
Other organ 109 (20)
Diagnosed by doctors abroad 11 (2)
3 History of TB disease & treatment
Previously diagnosed TBa 59 (10.8)
Previously treated LTBIa 24 (4.4)
4 The risk group of TB
TB contacts 29 (5.3)
Immigrants 68 (12.5)
Asylum seekers 87 (16)
Illegal immigrants 14 (2.6)
Homeless individual 15 (2.8)
Alcohol dependence 8 (1.5)
Substance abuse 18 (3.3)
Health care workers 4 (0.7)
Travelers from/in endemic areas





Table 1 Characteristics of patients (n = 545) (Continued)





Organ transplantation 2 (0.4)
Information: amissing value: Gender 1 (0.2%), Country of birth 2 (0.4%), Newly
diagnosed TB 53 (9.7%), previous LTBI treatment 58 (10.6%); bUrban domicile:
Amsterdam, Rotterdam, the Hague and Utrecht; TB, tuberculosis; ETB, extra-
pulmonary tuberculosis; PTB, pulmonary tuberculosis; LTBI, latent
tuberculosis infection
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Table 2 Predictors for the unsuccessful treatment of tuberculosis among drug-resistant tuberculosis patients (n = 545)





Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
1 Socio-demographic
Malea 275 (53) 20 (80) 3.55 (1.31–9.60) 0.008 2.30 (0.79–6.69) 0.13
Age (years): 0.88 Not included –
18–24 101 (19.4) 5 (20) Ref. – – –
25–64 385 (74) 19 (76) 0.99 (0.36–2.74) – – –
65+ 34 (6.5) 1 (4) 0.59 (0.06–5.27) – – –
Foreign-born patientsa 447 (86.3) 22 (88) 1.12 (0.34–3.99) 0.81 Not included –
Urban domicileb 174 (33.5) 12 (48) 0.55 (0.24–1.22) 0.13 1.85 (0.74–4.63) 0.19
2 Current TB diagnosis
Pulmonary diagnosis: 0.07 0.39
ETB 188 (36.2) 3 (12) Ref. – Ref. –
PTB 265 (51) 18 (72) 4.26 (1.24–14.66) – 2.44 (0.66–9.05) –
ETB + PTB 67 (12.9) 4 (16) 3.74 (0.82–17.15) – 2.50 (0.49–12.66) –
Type of TB location: 0.20 Not included –
Lungs 313 (60.2) 20 (80) 2.48 (0.92–6.71) – – –
Miliary and central nervous system 13 (2.5) 0 (0) n/a – – –
Others 194 (37.3) 5 (20) Ref. – – –
Diagnosed by doctors abroad 11 (2.1) 0 (0) n/a – – –
Type of resistance: 0.03 0.05
Isoniazid mono−/poly-resistant 365 (70.2) 10 (40) Ref. – Ref. –
Rifampicin mono−/poly-resistant 16 (3.1) 1 (4) 2.28 (0.28–18.9) – 1.68 (0.19–15.22) –
Pyrazinamide/ ethambutol mono-resistant 43 (8.3) 3 (12) 2.54 (0.68–9.61) – 2.96 (0.73–12.07) –
MDR-TB 92 (17.7) 11 (44) 4.36 (1.80–10.59) – 4.43 (1.70–11.60) –
XDR-TB 4 (0.8) 0 (0) n/a – n/a –
3 History of TB disease & treatment
Previously diagnosed with TBa 55 (11.7) 4 (17.4) 1.59 (0.52–4.83) 0.51 Not included –
Previously treated LTBIa 24 (5.2) 0 (0) n/a 0.62 Not included –
4 Risk group of TB
TB contacts 27 (5.2) 2 (8) 1.59 (0.36–7.09) 0.54 Not included –
Immigrants 65 (12.5) 3 (12) 0.96 (0.28–3.28) 0.94 Not included –
Asylum seekers 81 (15.6) 6 (24) 1.71 (0.66–4.42) 0.26 Not included –
Illegal residence persons 13 (2.5) 1 (4) 1.63 (0.20–12.94) 0.49 Not included –
Homeless individuals 9 (1.7) 6 (24) 17.93 (5.79–55.50) 0.000 9.10 (2.32–35.74) 0.002
Alcohol dependence 5 (1) 3 (12) 14.05 (3.15–62.54) 0.004 4.35 (0.60–31.31) 0.14
Substance abuse 12 (2.3) 6 (24) 13.37 (4.53–39.43) 0.000 6.66 (1.72–25.82) 0.006
Health care workers 4 (0.8) 0 (0) n/a 0.66 Not included –
Travellers from/in endemic areas for more than 3month 19 (3.7) 0(0) n/a 0.33 Not included –
Prisoners 10 (1.9) 2 (8) 4.44 (0.92–21.42) 0.10 0.43 (0.05–3.94) –
5 Comorbidities
Diabetes 17 (3.3) 1 (4) 1.23 (0.16–9.65) 0.58 Not included –
Malignancy 11 (2.1) 0 (0) n/a 0.46 Not included –
Insufficient renal function or on dialysis 5 (1) 0 (0) n/a 0.62 Not included –
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found in patients with male gender, homelessness, and
substance abuse in the univariate analysis. In the final
model, male gender (OR 9.80; 95%CI 1.18–81.68) and
substance abuse (OR 7.50; 95%CI 1.07–52.37) were
identified as independent predictors for poor TB treat-
ment outcomes in MDR-TB cases. A Hosmer-Lemeshow
test was shown on p-value of 1 (Table 4).
Discussion
Our study demonstrated that the overall prevalence and
poor outcomes of DR-TB cases among adults in the
Netherlands were relatively low. Most DR-TB cases were
foreign-born, newly diagnosed TB and isoniazid mono
−/poly-resistant TB patients. Though the numbers were
low, we identified that MDR-TB, homelessness, and
substance abuse were statistically significant predictors
for unsuccessful treatment, while miliary and CNS-TB
were analysed as predictors for TB-associated mortality
among overall DR-TB cases. Additionally, we noted that
patients with male gender and substance abuse were
more likely to have a poor outcome after MDR-TB treat-
ment. Among all DR-TB cases, we found that previously
diagnosed TB patients, illegal immigrants, travelers
from/in endemic areas and prisoners were more likely
not to be evaluated for their treatment outcome, which
indicates potential risk of poor outcome treatment.
Our study showed that the Netherlands has a low preva-
lence of DR-TB and poor DR-TB treatment outcomes.
Several studies described that the prevalence of DR-TB
and MDR-TB across the 27 European Union (EU) and
European Economic Area (EEA) countries were 10 and
2%, respectively [18], while our data demonstrated that
the Netherlands has a 5.3% prevalence of DR-TB and a 1%
prevalence of MDR-TB. In case of MDR-TB, the treatment
success rate in the Netherlands was 88%, which is higher
than the globally reported rates (46–58%) [3] and the 27
EU/EEA countries (48%) [18].
Our study determined that homelessness and substance
abuse are risk factors for having an unsuccessful TB
treatment outcome in overall DR-TB patients. Homeless
patients are faced with several problems, such as unstable
accommodation, lack of infection awareness, difficulties of
accessing healthcare services, stigmatization, problems
with access to proper nutrition and suffering from
comorbidities [19]. Those problems can lead to increasing
discontinuation rate and non-adherence to the medica-
tion. A published review stated that drug users are associ-
ated with vulnerable TB condition, such as homelessness
and HIV status [20]. It can be argued that homeless pa-
tients are a susceptible group to have poor TB treatment
outcomes. Although due to low numbers of outcomes, we
observed statistically significant associations. However, the
precision of the estimates was low, especially for the fac-
tors homelessness and substance abuse.
CNS and miliary TB should be a concern in the man-
agement of TB as their mortality risk was the highest of
all TB forms. This finding was supported by a study in
Denmark [21] that showed that CNS-TB was a factor
strongly associated with mortality in TB patients.
Another study reported that CNS-TB was frequently
accompanied with miliary TB [22]. The multifaceted
problems in the management of CNS-TB relate to delays
in clinical recognition, diagnosis, treatment and drug
penetration in cerebrospinal fluid, have been determined
as the main issues to improve successful treatment [23].
As expected, although isoniazid mono−/poly-resistant
TB was presented in the majority of cases in this study,
MDR-TB cases tend to have more frequently the
unsuccessful treatment outcome. Additional use of mox-
ifloxacin in first-line TB regimen may give a positive ef-
fect for the outcome of isoniazid mono−/poly-resistant
TB patients. A meta-analytical study that included data
from the Netherlands supported that addition of a
fluoroquinolone to 6 months or more of first-line regi-
men was associated with significantly greater treatment
success [24]. On the other hand, the complexity of the
MDR-TB treatment regimen that uses a combination of
first- and second-line drugs based on susceptibility test-
ing can result in unsuccessful treatment. The treatment
is longer, less effective and less tolerable than standard
treatments, and involves injectable drugs as well. Hence,
adverse events can occur among MDR-TB patient and
are a factor in the decision to discontinued treatment.
We also found that males and substance abuse are
associated with poor MDR-TB treatment outcomes. The
finding of an association between gender and tubercu-
losis treatment outcomes remains a contested debate.
Several studies have reported that there is no association
Table 2 Predictors for the unsuccessful treatment of tuberculosis among drug-resistant tuberculosis patients (n = 545) (Continued)





Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
Organ transplantation 2 (0.4) 0 (0) n/a 0.76 Not included –
Information: *The cases were analysed using backward elimination method in the multivariate analysis; Hosmer & Lemeshow test 0.88; n/a: not applicable due to
small number of event; Ref.: Reference; Not included: the predictor was not included due to p-value > 0.15 in the univariate analysis; amissing value: Gender 1
(0.2%), Country of birth 2 (0.4%), Newly diagnosed TB 53 (9.7%), previous LTBI treatment 58 (10.6%); bUrban domicile: Amsterdam, Rotterdam, The Hague and
Utrecht; TB, tuberculosis; ETB, extra-pulmonary tuberculosis; PTB, pulmonary tuberculosis; MDR-TB, multidrug-resistant tuberculosis; XDR-TB, extensively drug-
resistant tuberculosis; LTBI, latent tuberculosis infection; CI, confidence interval
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Table 3 Predictors for mortality outcomes due to tuberculosis among drug-resistant tuberculosis patients (n = 545)
No Predictors TB-associated mortality Univariate analysis Multivariate analysis*
No
(n = 539; %)
Yes







Malea 292 (54.3) 3 (50) 0.84 (0.17–4.21) 0.83 Not included –
Age (years): 0.07 0.05
18–24 105 (19.5) 1 (16.7) Ref. – Ref. –
25–64 401 (74.4) 3 (50) 0.78 (0.08–7.63) – 0.65 (0.06–6.91) –
65+ 33 (6.1) 2 (33.3) 6.36 (0.56–72.44) – 8.24 (0.63–107. 05) –
Foreign-born patientsa 464 (86.4) 5 (83.3) 0.78 (0.09–6.83) 0.58 Not included –
Urban domicileb 183 (34) 3 (50) 1.95 (0.39–9.73) 0.42 Not included –
2 Current TB diagnosis
Pulmonary diagnosis: 0.23 Not included –
ETB 191 (35.4) 0 (0) n/a – – –
PTB 280 (51.9) 3 (50) 0.24 (0.05–1.23) – – –
ETB + PTB 68 (12.6) 3 (50) Ref. – – –
Type of TB location: 0.013 0.024
Lungs 329 (61) 4 (66.7) Ref. – Ref. –
Miliary and central nervous system 11 (2) 2 (33.3) 14.96 (2.47–90.52) – 15.60 (2.18–111.52) –
Others 199 (36.9) 0 (0) n/a – n/a –
Diagnosed by doctors abroad 11 (2) 0 (0) 0 0.72 Not included –
Type of resistance: 0.97 Not included –
Isoniazid mono−/poly-resistant 371 (68.8) 4 (66.7) Ref. – – –
Rifampicin mono−/poly-resistant 17 (3.2) 0 (0) n/a – – –
Pyrazinamide/ ethambutol mono-resistant 45 (8.3) 1 (16.7) 2.06 (0.23–18.85) – – –
MDR-TB 102 (18.9) 1 (16.7) 0.91 (0.10–8.23) – – –
XDR-TB 4 (0.7) 0 (0) n/a – – –
3 History of TB disease & treatment
Previously diagnosed with TBa 59 (12.1) 0 (0) n/a 0.41 Not included –
Previously treated LTBIa 24 (5) 0 (0) n/a 0.61 Not included –
4 The risk group of TB
TB contacts 29 (5.4) 0 (0) 0 0.56 Not included –
Immigrants 67 (12.4) 1 (16.7) 1.41 (0.16–12.24) 0.55 Not included –
Asylum seekers 86 (16) 1 (16.7) 1.05 (0.12–9.13) 0.96 Not included –
Illegal residence persons 13 (2.4) 1 (16.7) 8.09 (0.88–74.24) 0.15 8.87 (0.71–111.40) 0.09
Homeless individual 15 (2.8) 0 (0) n/a 0.68 Not included –
Alcohol dependence 8 (1.5) 0 (0) n/a 0.76 Not included –
Substance abuse 18 (3.3) 0 (0) n/a 0.65 Not included –
Health care workers 4 (0.7) 0 (0) n/a 0.83 Not included –
Travellers from/in endemic areas for more than 3month 19 (3.5) 0 (0) n/a 0.64 Not included –
Prisoners 12 (2.2) 0 (0) n/a 0.71 Not included –
5 Comorbidities
Diabetes 17 (3.2) 1 (16.7) 6.14 (0.68–55.46) 0.18 Not included –
Malignancy 11 (2) 0 (0) n/a 0.72 Not included –
Insufficient renal function or on dialysis 5 (0.9) 0 (0) n/a 0.81 Not included –
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between gender and treatment outcomes among DR-TB
patients [25–27]. In contrast, studies in Nigeria [28] and
Taiwan [29] found that male gender is associated with
poorer tuberculosis treatment outcomes, while a review
explained an opposite statement [30]. The disparity of
the result can be explained by differences in social,
cultural, economic and clinical factors between patients
and geographical area. Financial dependence, cultural
inequality and greater fear of the stigmatization make it
more difficult for women to access qualified medical
care in some areas [31, 32]. On the other hand, gender-
specific social role makes men to have more social con-
tact in other areas, thereby increasing the risk of TB
exposure [33]. Furthermore, clinical aspects can also
play a role in the treatment outcome. A study in Nigeria
[28] showed that male patients were older, while a study
in Taiwan [29] described that males were more likely to
smoke, have COPD, malignancy, cirrhosis, low body
weight, pleural effusion or hemoptysis. In our data, the
prevalence of the poor outcome in MDR-TB was higher
in males (10.68%) than females (0.97%). We found that
substance abuse was the only one characteristic that
associated with poor outcome in the male group, while
there was no characteristic associated with poor outcome
in the female group (see Additional file 1: Table S3).
Although substance abuse was indicated as a factor that
affected the poor outcome in the different gender, a
further study that considers social, cultural, economic and
clinical aspects is required to obtain a comprehensive
picture across geographical areas.
The present study indicated that most DR-TB patients
were foreign-born, with primary drug-resistant M. tb.
This finding can be explained by the fact that the most
DR-TB patients had a newly diagnosed TB Since the
Netherlands has a low TB prevalence, it seems that
immigration and activation of latent TB were essential
factors of DR-TB cases in the Netherlands.
Several potential limitations in our study need to be
mentioned. First, some potential predictors such as HIV
status, treatment delay, history of BCG vaccine, level of
education, the income of patients, and patients’ beliefs,
could not be analysed due to the unavailability of the
data for a large number of patients. Second, since the
data were collected from a national database, we relied
on administrative input without any direct investiga-
tion. Third, the low incidence of the study outcomes
(unsuccessful treatment and death) led to potential
overestimations and a wide confidence interval around
the odd ratios in some associations between predictors
and the outcomes. The inaccuracy of point estimate
may exist in the association between gender and poor
treatment outcome among MDR-TB patients. It is due
to the uncommon incidence of poor treatment outcome
in the female group. However, we identified that the
probability of poor treatment outcome was significantly
higher in the male (91.7%) than female group (8.3%).
Additionally, a factor that was associated with poor
treatment outcome in the MDR-TB group, i.e., sub-
stance abuse, was significantly dominated by male pa-
tients (Additional file 1: Table. S3). These reasons seem
to suggest that males are more likely to have poor treat-
ment outcome among MDR-TB patients. Fourth, ana-
lysis of the appropriateness of medication cannot be
performed due to lack of detailed treatment history and
regimen in the database. However, we believe that
integrating documentation and data collection of TB
information, supported with integrated information tech-
nology and a referral system of healthcare services in the
Netherlands, will minimize potential bias and results can
be generalized to the Dutch population. Importantly the
information may also be useful for low-incidence TB
countries in general.
A high success rate for MDR-TB treatment in the
Netherlands was constantly reported from the previous
studies [12, 13] to the present study. Integrated systems
and collaboration between all stakeholders may be the key
to this success. Municipal Public Health Services (MPHSs)
have an important role in controlling TB in the
Netherlands. Twenty-five MPHSs, staffed by public health
TB control officers, physicians, nurses, and administrative
staff, are spread widely across the Netherlands [34]. They
have the responsibility to diagnose, treat and monitor TB
and LTBI patients for TB control. Suspected TB patients
from the general practice or at-risk groups, such as immi-
grants, asylum seekers, and prisoners will have a TB exam-
ination in MPHSs to identify TB cases. A dedicated
hospital TB coordinator in the Netherlands manages TB
cases in the hospital setting. To optimize treatment
Table 3 Predictors for mortality outcomes due to tuberculosis among drug-resistant tuberculosis patients (n = 545) (Continued)
No Predictors TB-associated mortality Univariate analysis Multivariate analysis*
No
(n = 539; %)
Yes






Organ transplantation 2 (0.4) 0 (0) n/a 0.88 Not included –
Information: * The cases were analysed using entry method in the multivariate analysis; Hosmer & Lemeshow test 0.85; n/a: not applicable due to small number of
event; Ref.: Reference; Not included: the predictor was not included due to p-value > 0.15 in the univariate analysis; amissing value: Gender 1 (0.2%), Country of
birth 2 (0.4%), Newly diagnosed TB 53 (9.7%), previous LTBI treatment 58 (10.6%); bUrban domicile: Amsterdam, Rotterdam, The Hague and Utrecht; TB,
tuberculosis; ETB, extra-pulmonary tuberculosis; PTB, pulmonary tuberculosis; MDR-TB, multidrug-resistant tuberculosis; XDR-TB, extensively drug-resistant
tuberculosis; LTBI, latent tuberculosis infection; CI, confidence interval
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adherence, TB nurses in MPHSs have been trained as treat-
ment supporters in order to monitor drug adherence dur-
ing the treatment period. Two special hospitals for TB,
called modern TB centres, are available for long-term ad-
missions, socially problematic cases and clinically complex
patients, such as TB meningitis or M- and XDR-TB
patients [35]. If a contagious TB patient refuses treatment
and poses a risk to the general population, the patient can
be compulsorily isolated according to the Dutch Public
Health Act. TB centre Beatrixoord is designated by the
Dutch government for compulsory isolation. Moreover,
pharmacokinetics/pharmacodynamics modeling has been
Table 4 Predictors of poor outcomes of TB treatment among multidrug-resistant tuberculosis patients (n = 103)
No Predictors Non-Poor outcome
(n = 91; %)
Poor outcomeb
(n = 12; %)







Male 42 (46.2) 11 (91.7) 12.83 (1.59–103.57) 0.003 9.80 (1.18–81.68) 0.035
Age (years): 0.42 Not included –
18–24 26 (28.6) 2 (16.7) Ref. – – –
25–64 63 (69.2) 9 (75) 1.86 (0.38–9.19) – – –
65+ 2 (2.2) 1 (8.3) 6.50 (0.39–106.71) – – –
Foreign-born patientsd 89 (97.8) 12 (100) n/a 0.99 Not included –
Urban domicilec 21 (23.1) 5 (41.7) 0.42 (0.12–1.46) 0.17 Not included –
2 Current TB diagnosis
Pulmonary diagnosis: 0.88 Not included –
ETB 21 (23.1) 2 (16.7) Ref. – – –
PTB 55 (60.4) 8 (66.7) 1.53 (0.30–7.79) – – –
ETB + PTB 15 (16.5) 2 (16.7) 1.40 (0.17–11.08) – – –
Type of TB location: 0.71 Not included –
Lungs 65 (71.4) 8 (66.7) 0.95 (0.23–3.86) – – –
Miliary and central nervous system 3 (3.3) 1 (8.3) 2.56 (0.19–33.16) – – –
Others 23 (25.3) 3 (25) Ref. – – –
Diagnosed by a doctor abroad 5 (5.5) 0 (0) n/a 0.41 Not included –
3 History of TB disease & treatment
Previously diagnosed with TBa 18 (22.5) 4 (33.3) 1.72 (0.47–6.38) 0.47 Not included –
Previously LTBI treatmenta 5 (6.4) 0 (0) n/a 0.38 Not included –
4 The risk group of TB
TB contacts 4 (4.4) 1 (8.3) 1.98 (0.20–19.32) 0.47 Not included –
Immigrants 20 (22) 1 (8.2) 0.32 (0.04–2.65) 0.45 Not included –
Asylum seekers 27 (29.7) 4 (33.3) 1.18 (0.33–4.27) 0.75 Not included –
Illegal residence persons 5 (5.5) 0 (0) n/a 0.41 Not included –
Homeless individual 2 (2.2) 2 (16.7) 8.9 (1.13–70.26) 0.02 2.15 (0.19–24.28) 0.54
Alcohol dependence 0 (0) 1 (8.3) n/a 0.12 n/a –
Substance abuse 2 (2.2) 3 (25) 14.83 (2.18–100.78) 0.01 7.50 (1.07–52.37) 0.04
Health care workers 1 (1.1) 0 (0) n/a 0.72 Not included –
Travellers from/in endemic areas for more than 3month 5 (5.5) 0 (0) n/a 0.41 Not included –
Prisoners 4 (4.4) 0 (0) n/a 0.46 Not included –
5 Comorbidities
Diabetes 3 (3.3) 1 (8.3) 2.67 (0.26–27.92) 0.39 Not included –
Malignancy 2 (2.2) 0 (0) n/a 0.60 n/a –
Insufficient renal function or undergoing dialysis 0 (0) 0 (0) n/a n/a n/a –
Organ transplantation 0 (0) 0 (0) n/a n/a n/a –
Information: * The cases were analysed using backward step elimination method in the multivariate analysis; The Hosmer and Lemeshow test: 1.00; Ref.:
Reference; Not included: the predictor was not included due to p-value > 0.15 in the univariate analysis; amissing data: previously diagnosed TB: 11 (10.7%),
Previously treated LTBI: 14 (13.6%). LTBI: Latent Tuberculosis Infection. bPoor outcome of treatment is a combination of unsuccessful treatment and death
outcome due to tuberculosis; cUrban domicile: Amsterdam, Rotterdam, The Hague and Utrecht; n/a: not applicable due to small number of event; dForeign-born
countries: Somalia 25 (24.3%), Georgia 8 (7.8%), Russia 6 (5.8%), India 5 (49%), Others 57 (55.33%)
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used for therapeutic drug monitoring (TDM) in the MDR-
TB treatment for years [36]. Since the treatment can be up
to 24-month treatment, the TDM supported for shortening
the regimen due to low drug exposure as well as improve
safety and efficacy of the drugs [37].
However, to optimize treatment outcome among DR-
TB patients, special attention should be given to patients
with MDR-TB, homelessness, substance abuse, as well as
miliary and CNS-TB. Admission of these patients to a
modern TB centre may be an option to intensify the
treatment and monitoring of these high-risk patients. It
can also prevent further development of drug resistance
and transmission of tuberculosis in the community [35].
The treatment management for these patients should
not only focus on medical support but also on social
support. Treatment should not only be seen from the
perspective of delivery to the patients but should also be
seen from a comprehensive care perspective that should
consider the patient’s ability to take medicine, to make a
right life choice, and the treatment should support their
circumstances to ensure an adherence to the treatment
and an improvement in the quality of life [20, 35].
Conclusions
We observed a low incidence of poor tuberculosis treat-
ment outcomes among DR-TB patients. The majority of
DR-TB cases were foreign-born patients with a newly di-
agnosed TB. To avoid unsuccessful treatment amongst
DR-TB patients in the Netherlands; special attention
should be given to patients with MDR-TB, homelessness,
and substance abuse. Furthermore, miliary and CNS TB
treated in general hospitals should be monitored care-
fully and/or treated together with TB specialists, or ad-
mitted to a modern TB center, to prevent premature
mortality due to TB. We also identified that patients
with male gender and substance abuse were more likely
to have poor MDR-TB treatment outcomes. Close moni-
toring should be given to DR-TB patients with previous
TB diagnosis, illegal status, traveling status from/in en-
demic areas and prisoner status to decrease the number
of not-evaluated patient outcome. Further studies are re-
quired to identify critical factors for poor TB treatment
outcomes, particularly in identified high-risk groups.
Additional file
Additional file 1: Table S1. The operational definition of study. Table
S2. Characteristics of not-evaluated patients (n = 573). Table S3. Poor
outcome of TB treatment between males and females among MDR-TB
patients (N = 103). (PDF 391 kb)
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